𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

✍ Scribed by Peter Jenner

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
137 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A controlled investigation of current an
A controlled investigation of current and premorbid personality: Characteristics of Parkinson's disease patients
✍ Dr. Guila Glosser; Christopher Clark; Bruce Freundlich; Lori Kliner-Krenzel; Phy 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB

## Abstract It has been suggested that before development of motor symptoms, Parkinson's disease (PD) patients with idiopathic display a specific cluster of personality traits consisting of increased rigidity, conscientiousness, industriousness, orderliness, and cautiousness. The idea of such a dis

Clinical rating of dyskinesias in Parkin
Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale
✍ Peter Hagell; Håkan Widner 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 2 views

Drug-induced dyskinesias (DID) manifested as hyperkinetic and/or dystonic movements or postures are common problems in Parkinson's disease (PD). Novel therapeutic interventions may offer possibilities to counteract these common adverse effects of an otherwise necessary treatment. To be able to evalu

Alendronate and vitamin D2 for preventio
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
✍ Yoshihiro Sato; Jun Iwamoto; Tomohiro Kanoko; Kei Satoh 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

The above article, published online on 14 March 2006 in Wiley Online Library (wileyonlinelibrary.com), and in Volume 21, Issue 7, Pages 924–929, has been retracted by agreement between the authors, the Editor‐in‐Chief, Jose A. Obeso, and Wiley Periodicals, Inc. The retraction has been agreed due to

Treatment of insomnia in Parkinson's dis
Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo
✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being co

Safety and efficacy of perampanel in adv
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
✍ Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschla 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the compan